Supplementary File 1: Questionnaire on HBsAg quantification use

Where do you practice? :|___| Outlying Health Center
Practice

Do you prescribe HBsAg quantification to all of your patients infected with chronic hepatitis
B?
|___| Private
Practice
|___|
Public
|___| No
|___|
Yes
o
o
If No : Please indicate the reason(s) for non-prescription

Difficulty accessing HBsAg quantification |___|

Invalid dosage |___|

Test not reimbursable

Useless in HBV follow-up of chronic hepatitis B |___|

Useless in treatment follow-up of chronic hepatitis B |___|
If Yes : Please indicate the reason(s) for prescription

In combination with HBV genotype

In combination with HBV viral load |___|

In combination with diagnosis of liver fibrosis
Fibrotest |___|

|___|
|___|
Fibroscan|___|
Liver biopsy|___|

To identify inactive carriers of HBV

Before the beginning of the treatment:

Used at week 12 or week 24 for Stopping Rule :|___|

Used at week 12 or week 24 for treatment continuation :|___|

To establish the treatment duration : |___|

Used in case of discontinuation of treatment: |___|
|___|
PeG IFN|___|
NUCs |___|
Have you already prescribed HBsAg quantification in HBV Delta coinfected patients?
|___|
No
|___|
Yes

If you prescribe HBsAg quantification, where are the HBsAg quantification tests performed?
|___|Internal laboratory |___|By a
specialized laboratory

Method used:

If you do not prescribe HBsAg quantification, would you be interested in suggesting this test
to your patients?
|___| No
|___| Yes
(Roche, Elecsys) |___|
(Abbott, Architect ) |___|